)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Pharvaris (PHVS) investor relations material
Pharvaris Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary3 Dec, 2025
Study background and design
RAPIDe-3 was a global, double-blind, placebo-controlled, crossover Phase 3 study evaluating deucrictibant immediate release capsule (20 mg) for on-demand treatment of hereditary angioedema (HAE) attacks, enrolling 134 participants (124 adults, 10 adolescents) from 24 countries and including all HAE subtypes and both on-demand and prophylactic patients.
The study population was diverse, with a median age of 38 years, 70% Caucasians, 14% Asians, 7% Black or African Americans, and 97% having HAE Type 1 or 2.
Each participant treated two qualifying attacks, with efficacy analyses based on 88 paired attacks.
Approximately 23% of patients were on long-term prophylactic treatment, mainly lanadelumab.
The study included patients on or off long-term prophylaxis and all HAE subtypes, including those with normal C1 inhibitor.
Efficacy results
Deucrictibant met the primary endpoint, achieving a median onset of symptom relief at 1.28 hours versus over 12 hours for placebo (p<0.0001).
End-of-progression was achieved in a median of 17.47 minutes for deucrictibant versus 228.67 minutes for placebo (p<0.0001).
Substantial symptom relief was reached in a median of 2.41–2.85 hours, and complete symptom resolution occurred in 11.95 hours with deucrictibant, both significantly faster than placebo.
By 4 hours, 85% of deucrictibant-treated attacks achieved symptom relief, compared to 30% for placebo.
83% of attacks were treated with a single capsule, and 93.2% did not require rescue medication.
Safety and tolerability
Deucrictibant was well tolerated, with most adverse events being mild or moderate and no discontinuations due to treatment-emergent adverse events.
Two serious adverse events occurred in each group, but none led to discontinuation; no fatal events or treatment-related serious adverse events were reported.
TEAEs were reported in 24% of deucrictibant-treated participants, with one severe and one life-threatening event.
No safety signals were identified from adverse events, labs, ECG, or vital signs.
Deucrictibant's unique value proposition
Strategy for combined on-demand and prophylactic use
Regulatory confidence from RAPIDe-3 data
What distinguishes deucrictibant from Ekterly?
How important is 'end of progression' to patients?
Impact of dual on-demand/prophylaxis strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Pharvaris earnings date
Q4 20252 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, particularly hereditary angioedema (HAE). The company specializes in creating oral bradykinin B2 receptor antagonists, offering alternatives to existing injected treatments. Its key developments include PHVS416, a soft capsule for on-demand use during acute HAE attacks, and PHVS719, an extended-release tablet aimed at preventing such attacks. Pharvaris operates primarily in the Netherlands, Switzerland, and the United States. The company is headquartered in Leiden, the Netherlands, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage